CRISPR-Cas9 System In Vivo Delivery to Combat HBV

Jahanzaib Ali (), Husnain Aslam () and Abida Yousuf ()

BIOEDUSCIENCE, 2023, vol. 7, issue 3, 339-349

Abstract: Background: Hepatitis B Virus (HBV) infection remains a major global health issue despite the availability of HBV vaccine. The novel CRISPR-Cas9 gene editing technology efficiently helps to cure HBV by disruption or cleavage of HBV DNA. Aims: Several in vitro and in vivo studies have demonstrated the effectiveness of HBV-specific clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein 9 (CRISPR/Cas9) systems in cleaving HBV DNA. Methods: In vivo, delivery of the CRISPR/Cas9 system at target sites remains a major challenge that needs to be resolved before its clinical application in gene therapy for HBV. Results: In this review article, we comprehensively evaluate the progress, challenges, and therapeutic potential of CRISPR-Cas9 gene therapy for HBV using adeno-associated virus (AAV) vectors as delivery vehicles. Conclusion: The CRISPR-CAS9, HBV, AAV, delivery methods of CRISPR-CAS9 component in vivo, challenges, and future perspectives in harnessing this innovative technology to combat HBV infection.

Keywords: hepatitis B virus; CRISPR/Cas9 delivery; AAV vectors; in vovo gene editing (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journal.uhamka.ac.id/index.php/bioeduscience/article/view/12693 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:apn:bionce:v:7:y:2023:i:3:p:339-349:id:12693

Access Statistics for this article

BIOEDUSCIENCE is currently edited by Susilo

More articles in BIOEDUSCIENCE from Universitas Muhammadiyah Prof. Dr. Hamka
Bibliographic data for series maintained by Susilo ().